Company intelligence / Profile preview

RohnerChem

Pratteln, Basel-Landschaft, Switzerland

Ownership: Private
Employees: ~200
Development stage: Other

Overview

RohnerChem ceased operations on June 24, 2024, after 113 years in business. The company was shut down by local authorities due to recurrent environmental issues at its Pratteln site, including groundwater contamination from industrial wastewater. Prior to closure, over 80% of revenue came from pharmaceutical clients, with approximately 70% from active pharmaceutical ingredient (API) synthesis and 30% from intermediates.

Modalities: Small molecule
Industry: Contract Manufacturing Organization

Partnerships

Solvias (2011 partnership for custom research and manufacturing services)Evocatal (2012 strategic partnership for enzymatic chemistry development)

Beyond the preview

Go deeper on RohnerChem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RohnerChem.

Explore the full profile